Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations

Drugs and Aging

Volumn 10, Issue 4, 1997, Pages 259-277

  Mörikc, Klaus ^a   Schwab, Matthias ^a   Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CREATININE; GENTAMICIN; NEOMYCIN; NETILMICIN; TOBRAMYCIN; VANCOMYCIN;

AGING; BIOEQUIVALENCE; BODY COMPOSITION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG OVERDOSE; DRUG USE; ELDERLY CARE; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE INFECTION; HUMAN; INFLAMMATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAPLEURAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PAIN; PHLEBITIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0030947798     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710040-00003     Document Type: Review

References (192)

1. Knight JA. The process and theories of aging. Ann Clin Lab Sci 1995; 25: 1-12
2. Shay JW. Aging and cancer: are telomeres and telomerase the connection? Mol Med Today 1995; 1: 378-84
3. Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol 1992; 32: 271-302
4. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7: 10-8
5. Schenker S. The aging liver. In: Abrams WB, Beers MH, Berkow R, editors. The Merck manual of geriatrics. 2nd ed. Whitehouse Station (NJ): Merck & Co. Inc., 1995: 696-9
6. Macias-Nuñez JF, Cameron JS. Renal function in the elderly. In: Cameron S, Davidson A, editors. Oxford textbook of clinical nephrology. Oxford: Oxford Medical Publishers, 1992; 56-70
7. Davies DF, Shock NW. Age changes in glomerular filtration rate, effect of renal plasma flow and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496-507
8. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in man: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-63
9. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-85
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
11. Smythe M, Hoffman J, Kizy K, et al. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm 1994; 51: 198-204
12. Rowland M, Tozer TN. Clinical pharmacokinetics, concepts and applications. 3rd ed. Baltimore (MD): Lea & Febiger, 1995
13. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing: fourth international supplement. NCCLS document M100-S4. Villanova (PA): NCCLS, 1992
14. Lerner SA, Gaynes RP, Nordström L. Aminoglycosides. In: Gorbach SL, Barlett JG, Blacklow NR, editors. Infectious diseases. Philadelphia: W.B. Saunders Company, 1992: 188-211
15. Moellering Jr RC. Clinical microbiology and the in vitro activity of aminoglycosides. In: Whelton A, Neu HC, editors. The aminoglycosidcs: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 65-95
16. Moellering Jr RC. In vitro antibacterial activity of the aminoglycoside antibiotics. Rev Infect Dis 1983; 5 Suppl.: S212-32
17. Betts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984; 100: 219-22
18. Kucers A, Bennett NMcK. Kanamycin, gentamicin, tobramicin, amikacin, sisomicin, and netilmicin. In: Kucers A, Bennett NMcK, editors. The use of antibiotics: a comprehensive review with clinical emphasis, 4th ed. London: William Heinemann Medical Books, 1987: 601-750
19. Cunha BA. Aminoglycosidcs: current role in antimicrobial therapy. Pharmacotherapy 1988; 8: 334-50
20. Atkinson BA. Species incidence and trends of susceptibility to antibiotics in the United States and other countries: MIC and MBC. In: Lorian V, editor. Antibiotics in laboratory medicine. 2nd ed. Baltimore (MD): Williams & Wilkins, 1986: 995-1150
21. Young LS, Hewitt WL. Activity of live aminoglycoside antibiotics in vitro against Gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother 1973; 4: 617-25
22. Lortholary O, Tod M, Cohen Y, et al. Aminoglycosides. Med Clin North Am 1995; 79: 761-91
23. Taber HW, Muller JP, Miller PE, et al. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 1987; 51: 439-57
24. Hannock REW, Bellido F. Antibiotic uptake: unusual results for unusual molecules. J Antimicrob Chemother 1992; 29: 235-9
25. Jackson GE, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990; 162: 408-13
26. Weisblum B, Davies J. Antibiotic inhibitors of the bacterial ribosome. Bacteriol Rev 1968; 32 Suppl.: 493-528
27. Davies J, Gorini L, Davies BD. Misreading of RNA code words induced by aminoglycoside antibiotics. Mol Pharmacol 1965; 1: 93-106
28. Byran LE, Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother 1983; 23: 835-45
29. Hummel H, Böck A. Ribosomal changes resulting in antibiotic resistance. In: Byran LE, editor. Microbial resistance to drugs: handbook of experimental pharmacology. Vol. 91. Berlin: Springer-Verlag, 1989: 235-62
30. Busse H-J, Wöstmann C, Bakker EP. The bactericidal action of streptomycin: membrane permeabilization caused by the insertion of mistranslated proteins into the cytoplasmic membrane of Escherichia coli and subsequent caging of the antibiotic inside the cells due to degradation of these proteins. J Gen Microbiol 1992; 138: 551-61
31. Davies JE. Aminoglycoside-aminocyclitol antibiotics and their modifying enzymes. In: Lorian V, editor. Antibiotics in laboratory medicine. 2nd ed. Baltimore (MD): Williams & Wilkins, 1986: 790-809
32. Kadurugamuwa JL, Lam JS, Beveridge TJ. Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect. Antimicrob Agents Chemother 1993; 37: 715-21
33. Nicas TI, Handock REW. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediamine tetraacetate, polymyxin B, and gentamicin. J Bacteriol 1980; 143: 872-8
34. Bryan LE. Aminoglycosides resistance. In: Bryan LE, editor. Antimicrobial drug resistance. Orlando (FL): Academic Press, 1984: 241-77
35. Modolell J, Davies BD. Mechanism of inhibition of ribosomes by streptomycin. Nature 1969; 224: 345-8
36. Ozaki M, Mizushimu S, Nomura M. Identification and functional characterization of the protein controlled by the streptomycin-resistant locus in E. coli. Nature 1969; 222: 333-9
37. Eliopoulos GM, Wennersten C, Zighelboim-Daum S, et al. High-level resistance to gentamicin in clinical isolates of Streptococcus (enterococcus) faecium. Antimicrob Agents Chemother 1988; 32: 1528-32
38. Shaw KJ, Rather PN, Hare RS, et al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57: 138-63
39. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-82
40. Hustinx WNM, Hoepelman IM. Aminoglycoside dosage regimens: is once a day enough? Clin Pharmacokinet 1993; 25: 427-32
41. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 279-306
42. Crossley KB, Peterson PK. Infections in the elderly. In: Mandell GL, Bennetl JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 2737-42
43. Crossley KB, Peterson PK. Infections in the elderly. Clin Infect Dis 1996; 22: 209-15
44. Norma DC, Toledo SD. Infections in elderly persons. Clin Geriatr Med 1992; 8: 713-9
45. Yoshikawa TT. Empiric antimicrobial therapy. In: Yoshikawa TT, Norman DC, editors. Antimicrobial therapy in rhe elderly patient. New York: Marcel Dekker Inc., 1994: 469-77
46. Yoshikawa TT, Norman DC. Treatment of infections in elderly patients. Med Clin North Am 1995; 79: 651-61
47. Begg EJ, Barclay ML. Aminoglycosides: 50 years on. Br J Clin Pharmacol 1995; 39: 597-603
48. Chambers HF, Sande MA. The aminoglycosides. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1103-21
49. Zaske DE. Aminoglycosides. In: Yoshikawa TT, Norman DC, editors. Antimicrobial therapy in the elderly patient. New York: Marcel Dekker Inc., 1994: 183-235
50. Smith CR, Lipsky JJ, Laskin OL, et al. Double blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106-9
51. Neu HC. Clinical use of aminoglycosides. In: Whelton A, Neu HC, editors. The aminoglycosides: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 65-95
52. Buring JE, Evans DA, Mayrent SL, et al. Randomized trials of aminoglycoside antibiotics: quantitative overview. Rev Infect Dis 1988; 10: 951-7
53. Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173-9
54. Nicolle LE. Urinary tract infection in the elderly. J Antimicrob Chemother 1994; 33 Suppl. A: 99-109
55. Prat V, Horcickova M, Hatala M, et al. Single-dose treatment with netilmicin tor different clinical forms of urinary tract infection. Infection 1984; 12: 99-101
56. Caramalli S, Amprimo MC, Cavalli G, et al. Effect and pharmacokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections. Im J Clin Pharmacol Res 1991 ; 11: 55-65
57. Gorbach SL. Antimicrobial prophylaxis for appendectomy and colorectal surgery. Rev Infect Dis 1991; 13 Suppl. 10: S815-20
58. Briedis DJ, Robson HG. Comparative activity of netilmicin, genlamicin. amikacin, and tobramycin against Pseudomonas aeruginosa and enterobacteriaceae. Antimicrob Agents Chemother 1976; 10: 592-7
59. Tseng JT, Bryan LE. Mechanisms and spectrum of streptomycin in a natural population of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1972; 2: 136-41
60. Konishi H, Goto M, Nakamoto Y, et al. Tobramycin inactivation by carbenicillin, ticarcillin, and piperacillin. Antimicrob Agents Chemother 1983; 23: 653-7
61. Pittinger CB, Adamson R. Antibiotic blockade of neuromuscular function. Annu Rev Pharmacol 1972; 12: 169-84
62. Holtzman JL. Gentamicin and neuromuscular blockade [letter] Ann Intern Med 1976; 84: 55
63. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92-104
64. Sanders DB, Kim YI, Howard Jr JR. et al. Intercostal muscle biopsy studies in myasthenia gravis: clinical correlations and the direct effects of drugs in myasthenic serum. Ann N Y Acad Sci 1981; 377: 544-66
65. Hokkanen E. The aggravating effect of some antibiotics on the neuromuscular blockade in myasthenia gravis. Acta Neurol Scand 1964; 40: 346-52
66. Lietman PS, Smith CR. Aminoglycoside nephrotoxicity in humans. Rev Infect Dis 1983; 5 Suppl. 2: S284-92
67. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity: a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984; 13 Suppl. A: 9-22
68. Appel GB. Aminoglycoside nephroloxidty. Am J Med 1990; 88 Suppl. 3C: 16S-20S
69. Aronoff GR, Pottratz ST, Brier ME, et al. Aminoglycoside accumulation kinetics in rat renal parenchyma. Antimicrob Agents Chemother 1983; 23: 74-8
70. Hostetler KY, Hall LB. Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity. Proc Natl Acad Sci U S A 1982; 79: 1663-7
71. Carlier MB, Laurent G, Claes PJ, et al. Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: in vitro comparative studies. Antimicrob Agents Chemother 1983; 23: 440-9
72. Morin JP, Fresel J, Fillasre J-P, et al. Aminoglycoside actions on rat kidney lysosomes in vim and in vitro. In: Fillasre J-P, editor. Nephrotoxicity. New York: Masson, 1978: 253-68
73. Ngaha EO, Ogunleye IO. Studies on gentamicin-induced labilization of rat kidney lysosomes in vitro. Biochem Pharmacol 1983; 32: 2659-64
74. Laurent G, Toubeau G, Heuson-Stiennon JA, et al. Kidney tissue repair after nephrotoxic injury: biochemical and morphological characterization. CRC Crit Rev Toxicol 1988; 19: 146-83
75. Sens MA, Hazen-Martin DJ, Blackburn JG, et al. Growth characteristics of cultured human proximal tubule cells exposed to aminoglycoside antibiotics. Ann Clin Lab Sci 1989; 19: 266-79
76. Luft FC. Clinical significance of renal changes engendered by aminoglycosides in man. J Antimicrob Chemother 1984; 13 Suppl. A: 23-30
77. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients with aminoglycosides. Ann Intern Med 1984; 100: 352-7
78. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149: 23-30
79. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Spokane (WA): Applied Therapeutics, 1986: 331-81
80. Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev 1994; 13: 207-34
81. McMartin DN, Engel SC. Effect of aging on gentamicin nephrotoxicity and pharmacokinetics in rats. Res Commun Chem Pathol Pharmacol 1982; 38: 193-207
82. 2M) in evaluating nephrotoxicity of gentamicin. Clin Chim Acta 1981; 116: 25-34
83. Schentag JJ, Sutfin TA, Plaut ME, et al. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J Med 1978; 9: 201-10
84. Schentag JJ, Plaut ME. Patterns of urinary beta-2 microglobulin excretion by patients treated with aminoglycosides. Kidney Int 1980; 17: 654-61
85. Schentag JJ. Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients. J Clin Pharmacol 1983; 23: 473-83
86. Schentag JJ, Gengo FM, Plaut ME, et al. Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother 1979; 16: 468-74
87. Anderson RJ, Linas SL, Berns AS, et al. Nonoliguric acute renal failure. N Engl J Med 1977; 296: 1134-8
88. Luft EC, Bloch R, Sloan RS, et al. Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis 1978; 138: 541-5
89. Williams PD, Bennett DB, Gleason CR, et al. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987; 31: 570-4
90. Kaloyanides GJ. Antibiotic-related nephrotoxicity. Nephrol Dial Transplant 1994; 9 Suppl. 4: 130-4
91. Downs NJ, Neihart RE, Dolezal JM, et al. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149: 1777-81
92. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87
93. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-34
94. Gatell JM, San Miguel JG, Zamora L, et al. Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin. Antimicrob Agents Chemother 1983; 23: 897-901
95. Govaerts PJ, Claes J, Van De Heying PH, et al. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990; 52: 227-51
96. Fausti SA, Henry JA, Schaffer HI, et al. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992; 165: 1026-32
97. Huy ITB, Meulemans A, Wassef M, et al. Gentamicin persistence in rat endolymph and perilymph after a two-day constant infusion. Antimicrob Agents Chemother 1983; 23: 344-6
98. Huizing KH, de Groot JCMJ. Human cochlear pathology in aminoglycoside ototoxicity: a review. Acta Otolaryngol (Stockh) 1987; 436 Suppl.: 117-25
99. Matz GJ. Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 1993; 5: 705-12
100. Stupp H, Kupper K, Lagler H, et al. Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application. Audiology 1973; 12: 350-63
101. Ohtsuki K, Ohtani I, Aikawa T, et al. The ototoxicity and the accumulation in the inner ear of the various aminoglycoside antibiotics. Ear Res Jpn 1982; 13: 85-7
102. Dulon D, Aran JM, Zajic G, et al. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemolher 1986; 30: 96-100
103. Tran B, Huy P, Bernard P, et al. Kinetics of gentamicin uptake and release in the rat: comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986; 77: 1492-1500
104. Hu DN, Qui WQ, Wu BT, et al. Genetic aspects of antibiotic-induced deafness: mitochondrial inheritance. J Med Genet 1991; 28: 79-83
105. Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993; 21: 4174-9
106. Fischel-Ghodsian N, Prezant TR, Bu X, et al. Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. Am J Otolaryngol 1993; 14: 399-403
107. Black FO, Pesznecker RN. Vestibular ototoxicity: clinical considerations. Otolaryngol Clin North Am 1993; 5: 713-37
108. Lombarte A, Yan HY, Popper AN, et al. Damage and regeneration of hair cell ciliary bundles in a fish ear following treatment with gentamicin. Hear Res 1993; 64: 166-74
109. Forge A, Li L, Corwin JT, et al. Ultrastructural evidence for hair cell regeneration in the mammalian inner ear. Science 1993; 259: 1616-9
110. Anniko M, Bagger-Sjoback D, Wersall J, et al. Gentamicin binding to the isolated crista ampullaris of the guinea pig. Res Commun Chem Pathol Pharmacol 1982; 37: 333-42
111. Gatell JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987; 31: 1383-7
112. Manian FA, Stone WJ, Alford R. Adverse antibiotic effects associated with renal insufficiency. Rev Infect Dis 1990; 12: 2.36-49
113. Brummett RE, Fox KE. Studies of aminoglycoside ototoxicity in animal models. In: Whetton A, Neu HC, editors. The aminoglycosides: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 419-51
114. Smith CR, Lietman PS. Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother 1983; 23: 133-7
115. Kunin CM, Chalmers TC, Leevy CM, et al. Absorption of orally administered neomycin and kanamycin. N Engl J Med 1960: 262: 380-5
116. Cox CE. Gentamicin. Med Clin North Am 1970; 54: 1305-15
117. Breen KJ, Bryant RE, Levinson JD, et al. Neomycin absorption in man. Ann Intern Med 1972; 76: 211-8
118. Barza M, Lauermann M. Why monitor serum levels of gentamicin? Clin Pharmacokinet 1978; 3: 202-15
119. Lanao JM, Dominguez-Gil A, Tabernero JM, et al. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration. Im J Clin Pharmacol Ther Toxicol 1982; 20: 271-5
120. Wilson TW, Mahon WA, Inaba T, et al. Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal function. Clin Pharmacol Ther 1973; 14: 815-22
121. Beauchamp D, Gourde P, Bergeron MG. Subcellular distribution of gentamicin in proximal tubular cells, determined by immunogold labeling. Antimicrob Agents Chemother 1991; 35: 2173-9
122. Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin m obese subjects. J Infect Dis 1978; 138: 499-505
123. Fong IW, Fenton RS. Bird R. Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study. J Antimicrob Chemother 1981; 7: 81-8
124. Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21: 407-411
125. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977; 22: 364-70
126. Welling PG, Baumueller A, Lau CC, et al. Netilmicin pharmacokinetics after single intravenous doses to elderly male patients. Antimicrob Agents Chemother 1977; 12: 328-34
127. Bauer LA, Blouin RA. Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother 1981; 20: 587-9
128. Bauer LA, Blouin RA. Gentamicin pharmacokinetics: effect of aging in patients with normal renal function. J Am Geriatr Soc 1982; 30: 309-11
129. Bauer LA, Blouin RA. Influence of age on amikacin pharmacokinetics in patients without renal disease: comparison with gentamicin and tobramycin. Eur J Clin Pharmacol 1983; 24: 639-42
130. Zaske DE, Irvine R, Strand LM, et al. Wide interpatient variations in gentamicin dosage requirements for geriatric patients. JAMA 1982; 248: 3112-26
131. Matzke GR, Jameson JJ, Halstenson CE. Gentamicin disposition in young and elderly patients with various degrees of renal function. J Clin Pharmacol 1987; 27: 216-20
132. El-Sayed YM, Islam SI. Effect of age and renal function on gentamicin pharmacokinetic parameters. Int J Clin Pharmacol 1989; 27: 503-9
133. Lackner TE, Birge S. Accuracy of pharmacokinetic dose determination of gentamicin in geriatric patients. DICP Ann Pharmacother 1990; 24: 29-32
134. Vanhaeverbeek M, Siska G, Herchuelz A. Pharmacokinetics of once-daily amikacin in elderly patients. J Antimicrob Chemother 1993; 31: 185-7
135. Koo JM, Miller DR, Peterson CD. Gentamicin pharmacokinetics in elderly patients with normal renal function. J Pharm Technol 1994; 10: 14-17
136. Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton (IL): Drug Intelligence Publications, 1975: 82-4
137. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimes which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183-95
138. Sawchuk RJ, Zaske DE, Cipolle RJ, et al. Kinetic models for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 360-9
139. Benet LZ, Øie S, Schwartz. JB. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1707-92
140. Prins JM, Koopmans RP, Büller HR, et al. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis 1995; 14: 531-5
141. Zhanel GG, Hoban DJ, Harding GKM. The postantibiotic effect: a review of in vitro and in vivo data. DICP Ann Pharmacother 1991; 25: 153-63
142. Zhanel GG, Craig WA. Pharmacokinetic contributions to post-antibiotic effect: focus on aminoglycosides. Clin Pharmacokinet 1994; 24: 377-92
143. Gerber AU. Postantibiotic effect: an update and an outlook on clinical relevance. Curr Opin Infect Dis 1993; 6: 751-7
144. MacKenzie FM, Gould IM. The post-antibiotic effect. J Antimicrob Chemother 1993; 32: 519-37
145. Barza M, Ioannidis JPA, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338-45
146. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy: selection, administration and monitoring. Drugs 1994; 47: 902-13
147. Blaser J, König C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029-38
148. Gonzalez P, Aguado JM, Martin MA, et al. Once-daily aminoglycoside dosing [letter]. Lancet 1993; 341: 895
149. Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974; 6: 465-70
150. Nordström L, Ringberg H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990; 25: 159-73
151. Prins JM, Büller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9
152. Raz R, Adawi M, Romano S. Intravenous administration of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995; 14: 88-91
153. Blaser J, Simmen HP, Thurnheer U, et al. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother 1995; 36: 803-14
154. De Vries PJ, Verkooyen RP, Leguit P, et al. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9: 161-8
155. Fan ST, Lau WY, Teoh-Chan CH, et al. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother 1988; 22: 69-74
156. Hansen M, Achen F, Carstensen C, et al. Once versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomised controlled study of efficacy and safety. J Drug Devel 1988; 1 Suppl. 3: 119-24
157. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intraabdominal infections. J Antimicrob Chemother 1989; 23: 773-83
158. Mauracher EH, Lau WY, Kartowisastro H, et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther 1989; 11: 604-13
159. Muijsken MA, Vreede RW, van Dijk WC, et al. A randomized clinical study of efficacy and safety of once daily dosing versus conventional dosing of netilmicin in patients with severe infections. J Drug Devel 1988; 1 Suppl. 3: 145-6
160. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585-98
161. Sturm AW. Netilmicin in the treatment of Gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931-7
162. Ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58-66
163. Van der Auwera P, Meunier F, Ibrahim S, et al. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/ kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991; 35: 640-7
164. Colandra T, International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93
165. Giamarellou H, Yiallouros K, Petrikkos G, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic Gram-negative infections. J Antimicrob Chemother 1991; 27 Suppl. C: 73-9
166. Maller R, Ahrne H, Holmen C, et al. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. J Antimicrob Chemother 1993; 31: 939-48
167. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753-64
168. Vanhaeverbeek M, Siska G, Douchamps J, et al. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe Gram-negative infections in the elderly. Int J Clin Pharmacol 1993; 31: 153-6
169. Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 1993; 58: 63-72
170. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9
171. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22-7
172. De Broe ME, Verbist L, Verpooten GA. Influence of dosing schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991; 27 Suppl. C. 41-7
173. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399-405
174. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27: 32-48
175. Bates RD, Nahata MC. Once daily administration of aminoglycosides. Ann Pharmacother 1994; 28: 757-65
176. Cunningham R, Humphreys H. Once-daily gentamicin: translating theory into practice. Eur J Clin Pharmacol 1996; 50: 151-4
177. Marra F, Partovi N, Jewesson P. Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors? Drugs 1996; 52: 344-70
178. Dew RB, Susla GM. Once-daily aminoglycoside treatment. Infect Dis Clin Pract 1996: 5: 12-24
179. Galløe AM, Graudal N, Christensen HR, et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48: 39-43
180. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-25
181. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-9
182. Spector R, Park GD, Johnson GF, et al. Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345-53
183. Guglielmo BJ, Brooks GF. Antimicrobial therapy: cost-benefit considerations. Drugs 1989; 38: 473-80
184. Destache CJ. Use of therapeutic drug monitoring in pharmacoeconomics. Ther Drug Monit 1993; 15: 608-10
185. Pancoast SJ. Aminoglycoside antibiotics in clinical use. Med Clin North Am 1988; 72: 581-612
186. Meyer RD. Risk factors and comparisons of nephrotoxicity of aminoglycosides. Am J Med 1986; 80 Suppl. 6B: 119-25
187. Klotz, U, Godel A. Once-daily dosing of gentamicin: experience with therapeutic monitoring and Bayesian pharmacokinetics. Ther Drug Monit 1994; 16: 534-5
188. Janknegt R. Aminoglycoside monitoring in the once- or twice-daily era: the Dutch situation considered. Pharm World Sci 1993; 15: 151-5
189. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305
190. Burton ME, Brater DC, Chen PS, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985; 35: 349-53
191. Mailer R, Emanuelsson B-M, Isaksson B, et al. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis 1990; 22: 575-9
192. Maller R, Isaksson B, Nilsson L, et al. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother 1988; 22: 75-9